 | |
| Clinical data | |
|---|---|
| Other names | Bleomycin A5 |
| Pregnancy category |
|
| Routes of administration | intravenous, intra-arterial,intramuscular, intratumoral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | amidase |
| Eliminationhalf-life | 1.3 hours |
| Excretion | renal (25-50%) |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ECHA InfoCard | 100.031.221 |
| Chemical and physical data | |
| Formula | C57H89N19O21S2 |
| Molar mass | 1440.57 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pingyangmycin (also known asbleomycin A5) is anantitumorglycopeptide antibiotic belonging to thebleomycin family, which is produced byStreptomyces verticillus var. pingyangensis n.sp., avariety ofStreptomyces verticillus. It was discovered in 1969 atPingyang County ofZhejiang Province inChina, and was brought into clinical use in 1978.[1]
In China, pingyangmycin has largely superseded bleomycin A2 (commonly known as "bleomycin"), since according to Chinese sources it is more effective, costs less, is easier to get, can treat a larger variety ofcancers (such asbreast cancer andliver cancer) and causes lesslung injury.[2][3] Though pingyangmycin and bleomycin can each causepulmonary fibrosis, pingyangmycin's most seriousside effect - which it does not share with bleomycin - isanaphylactic shock, which is rare, but may happen even in a low dose, and can be fatal.[4] In addition, it causes a higher incidence offever than bleomycin; the occurrence of this complication in patients is between 20 and 50%.
